Pfizer Inc. (United States) holds 4 active US FDA Type II Drug Master Files and 62 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 9 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Pfizer Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/pfizer-inc

Overview

Pfizer Inc. is a leading pharmaceutical company dedicated to discovering, developing, and delivering innovative medicines to improve patients' lives. Arena Pharmaceuticals, Inc., now a subsidiary of Pfizer, focuses on developing unique therapies for treating immune-inflammatory diseases.

Therapeutic areas

VaccinesOncologyInternal MedicineHospitalRare DiseaseInflammation & Immunology

Active ingredients with DMF or CEP filings

Substances for which Pfizer Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Pfizer Inc. holds 4 active (66 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • ACTIVATED CALICHEAMICIN DERIVATIVEActive2015-12-11
  • PRASTERONE ACETATEActive2014-12-11
  • ALPHAMETHYL EPOXIDEActive1996-09-11
  • HEPARIN SODIUM USPActive1976-08-03
  • CABERGOLINE USPInactive2014-12-12
  • LIPITOR (ATORVASTATIN CALCIUM) 10MG, 20MG, 40MG, 80MG ORALTABLETSInactive2009-01-29
  • FLUMETHASONEInactive2001-08-01
  • OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • CEFOPERAZONE SODIUMInactive1998-09-01
  • OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • TROLEANDOMYCINInactive1998-09-01
  • METHACYCLINE HYDROCHLORIDEInactive1998-09-01
  • OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • ERYTHROMYCIN STEARATEInactive1998-09-01
  • PENICILLIN V POTASSIUMInactive1998-09-01
  • OXYTETRACYCLINEInactive1998-09-01
  • METHACYCLINE HYDROCHLORIDEInactive1998-09-01
  • DOXYCYCLINE HYCLATEInactive1998-09-01
  • AMPHOTERICIN BInactive1998-09-01
  • OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • PENICILLIN G BENZATHINEInactive1998-09-01
  • TROLEANDOMYCINInactive1998-09-01
  • DOXYCYCLINE HYCLATEInactive1998-09-01
  • OXYTETRACYCLINEInactive1998-09-01
  • TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • CARBENICILLIN INDANYL SODIUMInactive1998-09-01
  • AMPICILLIN TRIHYDRATEInactive1998-09-01
  • CLINDAMYCIN HYDROCHLORIDEInactive1998-09-01
  • TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • PENICILLIN G SODIUMInactive1998-09-01
  • DOXYCYCLINE HYCLATEInactive1998-09-01
  • TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • STREPTOMYCIN SULFATEInactive1998-09-01
  • PENICILLIN G PROCAINEInactive1998-09-01
  • OXYTETRACYCLINE CALCIUMInactive1998-09-01
  • TETRACYCLINEInactive1998-09-01
  • OXYTETRACYCLINE CALCIUMInactive1998-09-01
  • DOXYCYCLINE HYCLATEInactive1998-09-01
  • CARBENICILLIN INDANYL SODIUMInactive1998-09-01
  • TETRACYCLINEInactive1998-09-01
  • TETRACYCLINEInactive1998-09-01
  • PLICAMYCINInactive1998-09-01
  • ERYTHROMYCINInactive1998-09-01
  • VIOMYCIN SULFATEInactive1998-09-01
  • PENICILLIN V POTASSIUMInactive1998-09-01
  • OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
  • HYDROXY ACIDInactive1992-07-13
  • PREDNISOLONE SODIUM PHOSPHATEInactive1991-08-22
  • TRIAMCINOLONE ACETONIDEInactive1990-10-31

Showing the 50 most relevant of 66 Drug Master Files (active first). The full list is in the FDA DMF list.

Excipient Drug Master Files

Pfizer Inc. holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.

  • SULPHOBUTYLETHER BETA-CYCLODEXTRIN SODIUM (SBECD)Active1997-12-17

Registered manufacturing sites (9)

Physical sites registered with the US FDA and resolved to Pfizer Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • recall — Class II2025-08-27

    Lack of Assurance of Sterility.

  • recall — Class II2025-08-27

    Lack of Assurance of Sterility.

  • recall — Class II2025-08-06

    CGMP Deviations; particulates identified during visual inspection

  • recall — Class II2025-08-06

    CGMP Deviations; particulates identified during visual inspection

  • recall — Class II2025-07-02

    Discoloration; discolored solution from cracked vials

  • recall — Class II2024-07-03

    Lack of Assurance of Sterility-The potential for incomplete crimp seals.

  • recall — Class II2024-07-03

    Lack of Assurance of Sterility-The potential for incomplete crimp seals.

  • recall — Class I2024-01-24

    Presence of Particulate Matter; identified as glass

  • recall — Class I2024-01-24

    Presence of Particulate Matter; identified as glass

  • recall — Class I2024-01-24

    Presence of Particulate Matter; identified as glass

  • recall — Class I2023-11-15

    Presence of Particulate Matter: identified as glass.

  • recall — Class I2023-11-15

    Presence of Particulate Matter: identified as glass.

  • recall — Class I2023-11-15

    Presence of Particulate Matter: identified as glass.

  • recall — Class III2023-04-19

    Labeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.

  • recall — Class I2023-02-01

    Presence of Particulate Matter: Glass particulate matter detected in injectable.

  • recall — Class II2023-01-11

    Lack of assurance of sterility: Bags have the potential to leak.

  • recall — Class II2022-10-12

    Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.

  • recall — Class I2022-09-21

    Presence of particulate matter

  • recall — Class I2022-08-03

    Presence of particulate matter: particulate identified as a beetle.

  • recall — Class II2022-05-25

    CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

  • recall — Class II2022-05-25

    CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

  • recall — Class II2022-05-25

    CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2022-04-13

    CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

  • recall — Class II2021-12-08

    Lack of sterility assurance: bag has the potential to leak.

  • recall — Class II2021-09-29

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • recall — Class II2021-09-29

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • recall — Class II2021-09-29

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • recall — Class II2021-09-29

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • recall — Class II2021-08-11

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

  • recall — Class II2021-08-11

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

  • recall — Class II2021-08-11

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • recall — Class I2021-06-09

    Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP

  • recall — Class I2021-06-09

    Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP

  • recall — Class II2021-05-26

    Presence of Particulate Matter: particulate matter identified as an insect in one vial.

  • recall — Class II2020-08-12

    Lack of Assurance of Sterility; potential loose metal overseal crimp defects.

  • recall — Class III2020-07-01

    Failed Dissolution Specifications

  • recall — Class II2020-06-17

    Presence of Particulate Matter: particulate matter identified after reconstitution.

  • recall — Class II2020-03-11

    Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

  • recall — Class II2020-02-19

    Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.

  • recall — Class II2020-02-19

    Defective Container: confirmed customer reports for vials with loose metal overseal crimp defects, which may result in lack of assurance of sterility.

  • recall — Class II2020-02-19

    Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.

  • recall — Class II2019-12-18

    Labeling: Incorrect or Missing Lot and/or expiration date.

  • recall — Class II2019-10-16

    Lack of Assurance of Sterility: Bag has the potential to leak.

For suppliers

Is this Pfizer Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.